These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34382754)

  • 1. High-Throughput Screening Identifies Ascorbyl Palmitate as a SIRT2 Deacetylase and Defatty-Acylase Inhibitor.
    Hong JY; Cassel J; Yang J; Lin H; Weiser BP
    ChemMedChem; 2021 Nov; 16(22):3484-3494. PubMed ID: 34382754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A homogeneous time-resolved fluorescence screen to identify SIRT2 deacetylase and defatty-acylase inhibitors.
    Yang J; Cassel J; Boyle BC; Oppong D; Ahn YH; Weiser BP
    PLoS One; 2024; 19(6):e0305000. PubMed ID: 38913635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Dimerization on the Deacylase Activities of Human SIRT2.
    Yang J; Nicely NI; Weiser BP
    Biochemistry; 2023 Dec; 62(23):3383-3395. PubMed ID: 37966275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a novel small molecule that inhibits deacetylase but not defatty-acylase reaction catalysed by SIRT2.
    Kudo N; Ito A; Arata M; Nakata A; Yoshida M
    Philos Trans R Soc Lond B Biol Sci; 2018 Jun; 373(1748):. PubMed ID: 29685974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Peptide-Based Sirtuin Defatty-Acylase Inhibitors Identified by the Fluorescence Probe, SFP3, That Can Efficiently Measure Defatty-Acylase Activity of Sirtuin.
    Kawaguchi M; Ieda N; Nakagawa H
    J Med Chem; 2019 Jun; 62(11):5434-5452. PubMed ID: 31117516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unexpected small molecules as novel SIRT2 suicide inhibitors.
    Chen X; Zou Y; Wang J; Cao Z; Liu J; Li Y; Zhao Y; He B
    Bioorg Med Chem; 2020 Mar; 28(6):115353. PubMed ID: 32061485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous Inhibition of SIRT2 Deacetylase and Defatty-Acylase Activities via a PROTAC Strategy.
    Hong JY; Jing H; Price IR; Cao J; Bai JJ; Lin H
    ACS Med Chem Lett; 2020 Nov; 11(11):2305-2311. PubMed ID: 33214845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substrate-Dependent Modulation of SIRT2 by a Fluorescent Probe, 1-Aminoanthracene.
    Bi D; Yang J; Hong JY; Parikh P; Hinds N; Infanti J; Lin H; Weiser BP
    Biochemistry; 2020 Oct; 59(40):3869-3878. PubMed ID: 32941003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, in-vitro evaluation and molecular docking studies of novel indole derivatives as inhibitors of SIRT1 and SIRT2.
    Manjula R; Gokhale N; Unni S; Deshmukh P; Reddyrajula R; Srinivas Bharath MM; Dalimba U; Padmanabhan B
    Bioorg Chem; 2019 Nov; 92():103281. PubMed ID: 31561106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Set of Highly Sensitive Sirtuin Fluorescence Probes for Screening Small-Molecular Sirtuin Defatty-Acylase Inhibitors.
    Nakajima Y; Kawaguchi M; Ieda N; Nakagawa H
    ACS Med Chem Lett; 2021 Apr; 12(4):617-624. PubMed ID: 33859801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton.
    Sakai T; Matsumoto Y; Ishikawa M; Sugita K; Hashimoto Y; Wakai N; Kitao A; Morishita E; Toyoshima C; Hayashi T; Akiyama T
    Bioorg Med Chem; 2015 Jan; 23(2):328-39. PubMed ID: 25515955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. X-ray crystal structure guided discovery of new selective, substrate-mimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells.
    Yang LL; Wang HL; Zhong L; Yuan C; Liu SY; Yu ZJ; Liu S; Yan YH; Wu C; Wang Y; Wang Z; Yu Y; Chen Q; Li GB
    Eur J Med Chem; 2018 Jul; 155():806-823. PubMed ID: 29957526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct Comparison of SIRT2 Inhibitors: Potency, Specificity, Activity-Dependent Inhibition, and On-Target Anticancer Activities.
    Spiegelman NA; Price IR; Jing H; Wang M; Yang M; Cao J; Hong JY; Zhang X; Aramsangtienchai P; Sadhukhan S; Lin H
    ChemMedChem; 2018 Sep; 13(18):1890-1894. PubMed ID: 30058233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors.
    Khanfar MA; Quinti L; Wang H; Choi SH; Kazantsev AG; Silverman RB
    Eur J Med Chem; 2014 Apr; 76():414-26. PubMed ID: 24602787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of New SIRT2 Inhibitors by Utilizing a Consensus Docking/Scoring Strategy and Structure-Activity Relationship Analysis.
    Huang S; Song C; Wang X; Zhang G; Wang Y; Jiang X; Sun Q; Huang L; Xiang R; Hu Y; Li L; Yang S
    J Chem Inf Model; 2017 Apr; 57(4):669-679. PubMed ID: 28301150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-(Methyl(phenyl)amino)-N-(phenyloxyphenyl)acetamide structural motif representing a framework for selective SIRT2 inhibition.
    Kaya SG; Eren G; Massarotti A; Bakar-Ates F; Ozkan E; Gozelle M; Ozkan Y
    Drug Dev Res; 2024 Jun; 85(4):e22224. PubMed ID: 38867474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorogenic Assays for the Defatty-Acylase Activity of Sirtuins.
    Young Hong J; Cao J; Lin H
    Methods Mol Biol; 2019; 2009():129-136. PubMed ID: 31152400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a NanoBRET assay to validate inhibitors of Sirt2-mediated lysine deacetylation and defatty-acylation that block prostate cancer cell migration.
    Vogelmann A; Schiedel M; Wössner N; Merz A; Herp D; Hammelmann S; Colcerasa A; Komaniecki G; Hong JY; Sum M; Metzger E; Neuwirt E; Zhang L; Einsle O; Groß O; Schüle R; Lin H; Sippl W; Jung M
    RSC Chem Biol; 2022 Apr; 3(4):468-485. PubMed ID: 35441145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure activity study of S-trityl-cysteamine dimethylaminopyridine derivatives as SIRT2 inhibitors: Improvement of SIRT2 binding and inhibition.
    Radwan MO; Ciftci HI; Ali TFS; Koga R; Tateishi H; Nakata A; Ito A; Yoshida M; Fujita M; Otsuka M
    Bioorg Med Chem Lett; 2020 Oct; 30(19):127458. PubMed ID: 32755678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of bicyclic pyrazoles as class III histone deacetylase SIRT1 and SIRT2 inhibitors.
    Therrien E; Larouche G; Nguyen N; Rahil J; Lemieux AM; Li Z; Fournel M; Yan TP; Landry AJ; Lefebvre S; Wang JJ; MacBeth K; Heise C; Nguyen A; Besterman JM; Déziel R; Wahhab A
    Bioorg Med Chem Lett; 2015 Jun; 25(12):2514-8. PubMed ID: 25971769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.